We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
+15.75%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$1.54B
AUM Growth
+$40.4M
Cap. Flow
-$19.3M
Cap. Flow %
-1.25%
Top 10 Hldgs %
46.87%
Holding
259
New
90
Increased
52
Reduced
41
Closed
65

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$25.6M
2
TMP icon
Tompkins Financial
TMP
+$13.1M
3
AGEN
Agenus
AGEN
+$6.13M
4
MNKD icon
MannKind Corp
MNKD
+$5.33M
5
MDVN
MEDIVATION, INC.
MDVN
+$3.71M

Top Sells

Rank Stock Value
1
AEGR
Aegerion Pharmaceuticals
AEGR
+$28.4M
2
ABBV icon
AbbVie
ABBV
+$14.7M
3
ZTS icon
Zoetis
ZTS
+$14.2M
4
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$11.5M
5
ARWR icon
Arrowhead Research
ARWR
+$8.75M

Sector Composition

Rank Sector Weight
1 Miscellaneous 89.38%
2 Healthcare 10.49%
3 Financials 0.07%
4 Technology 0.07%
5 Energy 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMY icon
176
PUT
Bristol-Myers Squibb
BMY
$130B
$278K 0.02%
+60
New +$2.63K
DNDN
177
DELISTED
DENDREON CORPORATION
DNDN
$263K 0.02%
+89,800
New +$332K
ARWR icon
178
CALL
Arrowhead Research
ARWR
$10.9B
$250K 0.02%
+439
New +$1.69K
CASC
179
CALL
DELISTED
Cascadian Therapeutics, Inc.
CASC
$230K 0.01%
+186
New +$1.96K
TLPH icon
180
CALL
Talphera
TLPH
$62.8M
$215K 0.01%
+10
New +$2.18K
ARAY icon
181
CALL
Accuray
ARAY
$29.1M
$188K 0.01%
+254
New +$1.6K
ECYT
182
CALL
DELISTED
Endocyte, Inc. Common Stock
ECYT
$143K 0.01%
+107
New +$1.69K
SEEL
183
PUT
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
– –
0
– –
AGEN
184
CALL
Agenus
AGEN
$310M
$96K 0.01%
+18
New +$1.23K
CCXI
185
PUT
DELISTED
ChemoCentryx, Inc.
CCXI
$86K 0.01%
+155
New +$1.68K
SQNM
186
CALL
DELISTED
SEQUENOM INC NEW
SQNM
$78K 0.01%
+293
New +$984
SQNM
187
PUT
DELISTED
SEQUENOM INC NEW
SQNM
$55K ﹤0.01%
+205
New +$689
TENX icon
188
Tenax Therapeutics
TENX
$68.1M
$54K ﹤0.01%
+1
New +$59K
SQNM
189
DELISTED
SEQUENOM INC NEW
SQNM
$41K ﹤0.01%
+15,400
New +$51.7K
ATHX
190
PUT
DELISTED
Athersys, Inc. Common Stock
ATHX
$40K ﹤0.01%
+10
New +$425
CYTR
191
CALL
DELISTED
CytRx Corp
CYTR
$40K ﹤0.01%
+21
New +$310
ONCY
192
CALL
DELISTED
ONCOLYTICS BIOTECH INC
ONCY
$24K ﹤0.01%
+100
New +$277
ATHX
193
CALL
DELISTED
Athersys, Inc. Common Stock
ATHX
$22K ﹤0.01%
+5
New +$212
ABBV icon
194
CALL
AbbVie
ABBV
$459B
– –
-2,926
Closed -$12.1M
ABBV icon
195
AbbVie
ABBV
$459B
– –
-355,626
Closed -$14.7M
ABBV icon
196
PUT
AbbVie
ABBV
$459B
– –
-9,253
Closed -$38.3M
ALGN icon
197
CALL
Align Technology
ALGN
$10.7B
– –
-889
Closed -$3.29M
ALNY icon
198
CALL
Alnylam Pharmaceuticals
ALNY
$32.5B
– –
-468
Closed -$1.45M
ARWR icon
199
Arrowhead Research
ARWR
$10.9B
– –
-2,276,980
Closed -$8.75M
ASMB icon
200
Assembly Biosciences
ASMB
$560M
– –
-11,590
Closed -$1.67M
6 7
8
9 10

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q3 2013 Portfolio in Review

As of Q3 2013, Sabby Management held 259 positions worth $1.54B, up 2.7% from $1.5B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Sabby Management's Q3 2013 filing shows 90 new, 52 increased, 41 reduced and 65 closed positions. Its largest new stake was Tompkins Financial: 288,454 shares worth $1.02M. The largest sale was Aegerion Pharmaceuticals, an estimated $28.4M.

By sector, the portfolio is most concentrated in Miscellaneous at 89% of assets, up from 89% a quarter earlier, followed by Healthcare and Financials.

  • Sabby Management's largest Q3 2013 buy was Tompkins Financial: 288,454 shares worth $1.02M.
  • Sabby Management added most to Vertex Pharmaceuticals in Q3 2013, an estimated $25.6M increase.
  • Sabby Management's biggest Q3 2013 reduction was Aegerion Pharmaceuticals, cutting an estimated $28.4M.
  • Sabby Management fully exited AbbVie in Q3 2013, selling an estimated $14.7M.
  • Sabby Management's ten largest holdings make up 47% of its $1.54B portfolio in Q3 2013.
  • Sabby Management opened 90 new positions and closed 65 in Q3 2013.
  • Sabby Management's portfolio value rose 2.7% quarter-over-quarter to $1.54B.

Based on Sabby Management's 13F filing for Q3 2013, filed 14 Nov 2013.